Navigation Links
GenVec Reports Fourth Quarter And 2012 Year-End Financial Results
Date:3/22/2013

GAITHERSBURG, Md., March 22, 2013 /PRNewswire/ -- Today GenVec, Inc. (NASDAQ: GNVC) announced financial results for the fourth quarter and year ended December 31, 2012.  For the year ended December 31, 2012, the Company reported a net loss of $14.1 million, or $1.09 per share, compared with a net loss of $7.4 million, or $0.58 per share, for the year ended December 31, 2011. GenVec ended the year with $15.3 million in cash, cash equivalents, and short-term investments. 

"In 2012 we continued to make progress in our hearing restoration program, partnered with Novartis, and advanced the development of our product pipeline and core technologies," stated Cynthia Collins , GenVec's President and CEO.  "Other changes implemented since my joining GenVec in May were reducing our workforce to preserve capital and discontinuing spending on non-funded programs.  We continue to seek sources of non-dilutive funding to advance our programs and to reduce expenses to preserve cash."

2012 and Recent Corporate HighlightsHearing Restoration

  • We extended our Research Collaboration and License Agreement with Novartis.  Under the extension, Novartis will fund research at GenVec through January 2014 to support its hearing loss and balance disorders program.
  • RSV Vaccine

  • GenVec conducted a successful pre-IND interaction with the U.S. Food and Drug Administration (FDA) to obtain guidance on the development plan for its vaccine against respiratory syncytial virus (RSV).  The outcome of the pre-IND interaction was obtaining clarification on the nonclinical, clinical, and chemistry, manufacturing, and control (CMC) requirements that need to be met in order to submit an acceptable IND.
     
  • GenVec received a grant of approximately $590,000 over two years from the Natio
    '/>"/>

  • SOURCE GenVec, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. GenVec To Release First Quarter 2012 Financial Results And Conduct A Conference Call On May 10, 2012
    2. GenVec Appoints Cynthia Collins as President and CEO
    3. GenVec Reports Inducement Award
    4. GenVec Announces Conditional Approval of FMD Vaccine for Cattle
    5. GenVec to Release Second Quarter 2012 Financial Results and Conduct a Conference Call on August 9, 2012
    6. GenVec Reports Second Quarter 2012 Financial Results
    7. GenVec Reports Third Quarter 2012 Financial Results
    8. GenVec to Present at 25th Annual ROTH Conference
    9. GenVec To Release Fourth Quarter And Year-end 2012 Financial Results And Conduct A Conference Call On March 22, 2013
    10. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
    11. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/1/2015)... 1, 2015 Trinity Biotech plc (Nasdaq: ... of diagnostic products for the point-of-care and clinical ... Limited, its wholly-owned subsidiary (the "Issuer"), intends to ... million aggregate principal amount of Exchangeable Senior Notes ... institutional buyers pursuant to Rule 144A under the ...
    (Date:4/1/2015)... 1, 2015  Pittman Motors has significantly expanded ... PLG42K, PLG42S, PLG52, and PLG63 planetary gearboxes. These ... brushless DC motors and complement Pittman,s existing spur ... 35 standard motor-gearbox family combinations to the Pittman ... high torque loads with excellent efficiency and are ...
    (Date:4/1/2015)... MOUNTAIN VIEW, Calif. , April 1, ... ) announces that it has signed a definitive ... device company that develops, manufactures and sells minimally ... drainage of targeted areas within the gastrointestinal tract. ... The Xlumena portfolio includes the ...
    Breaking Medicine Technology:Trinity Biotech plc Announces Proposed Offering of $100 Million of Exchangeable Senior Notes due 2045 2Trinity Biotech plc Announces Proposed Offering of $100 Million of Exchangeable Senior Notes due 2045 3Trinity Biotech plc Announces Proposed Offering of $100 Million of Exchangeable Senior Notes due 2045 4Pittman Motors Expands PLG Planetary Gearbox Offering 2Boston Scientific Agrees to Acquire Xlumena 2Boston Scientific Agrees to Acquire Xlumena 3Boston Scientific Agrees to Acquire Xlumena 4Boston Scientific Agrees to Acquire Xlumena 5
    ... Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: ... specializing in the development, manufacturing, and marketing of ... that Shanghai Celgen Bio-Pharmaceutical Co., Ltd. ("Shanghai Celgen") ... interest, has received new drug registration approval for ...
    ... Cempra Pharmaceuticals, a developer of differentiated antibiotics, ... (IV) solithromycin demonstrates excellent tolerability and ... up to 800 mg.  Oral administration of solithromycin ... 1 studies.  The presentation will be at the ...
    Cached Medicine Technology:Simcere Announces Recent Progress of Qiangke's Registration 2Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 2Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 3Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 4Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 5Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 6Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 7
    (Date:4/1/2015)... 2015 After a particularly harsh winter, many ... can lead to costly damage, so Amica Insurance ... sharing the following suggestions from AAA: , , ... be inflated to the manufacturer’s recommended levels. , ... vibration and uneven tire wear can be signs of bad ...
    (Date:4/1/2015)... 2015 Taking an important step forward ... for Nursing Commission for Nursing Education Accreditation (NLN CNEA) ... first NLN CNEA Board of Commissioners. Working with executive ... 15-member board will provide leadership and direction to accreditation ... decisions for nursing programs that seek accreditation from the ...
    (Date:4/1/2015)... 2015 BioPlus Specialty Pharmacy ... has released a new app to keep health care ... chronic hepatitis C virus (HCV) infection. This ‘HCV Treatment ... from the American Association for the Study of Liver ... new direct-acting oral medications to treat HCV have been ...
    (Date:4/1/2015)... Seattle, WA (PRWEB) April 01, 2015 ... management and patient scheduling platform, today announced that CEO ... 2015 Annual HIMSS Conference & Exhibition in ... Outpatient Revenue Growth with Better Provider Care Coordination Strategies ... April 16 at 12 p.m. CDT. More than 38,000 ...
    (Date:4/1/2015)... Parents of teenaged and adolescent children might ... latest post discusses Teen Violence Related to Substance Abuse. ... Violence Awareness Month, the substance abuse treatment center has ... parents identify if there may be problems with their ... or alcohol. , “People learn how to establish healthy ...
    Breaking Medicine News(10 mins):Health News:Prepare for potholes with 7 tips from Amica Insurance 2Health News:NLN Commission for Nursing Education Accreditation (NLN CNEA) Announces Inaugural Commissioners 2Health News:NLN Commission for Nursing Education Accreditation (NLN CNEA) Announces Inaugural Commissioners 3Health News:BioPlus Specialty Pharmacy Releases ‘HCV Treatment Path’ App for Hepatitis C Providers 2Health News:SCI Solutions CEO Joel French and Northeast Georgia Health System to Present at HIMSS15 2Health News:SCI Solutions CEO Joel French and Northeast Georgia Health System to Present at HIMSS15 3Health News:SCI Solutions CEO Joel French and Northeast Georgia Health System to Present at HIMSS15 4Health News:Best Drug Rehabilitation Issues Toolkit for Teen Violence Related to Substance Abuse 2
    ... May 28 A new history of shock treatment (electroconvulsive ... Want You to Know About Shock Treatment" ( Rutgers University ... and Drug Administration,s failure to investigate the devices that administer ... due to the FDA,s recent decision to call on the ...
    ... The cardiovascular fitness level of cancer survivors is not ... Georgetown University Medical Cancer. That is the finding ... at the American College of Sports Medicine in Seattle. ... critical component of cancer survivorship, both during and after ...
    ... Society of Corporate Compliance and Ethics and Health ... critical time when the public, government leaders and ... bonus reforms, it appears that there is relatively ... according to a recent survey conducted by the ...
    ... One Medical, Inc. ("China Sky One Medical" or "the ... integrated pharmaceutical company in the People,s Republic of China ... representative for the North of the PRC and Mongolia, ... wholly-owned subsidiary of China Sky One, in Harbin on ...
    ... Four Million Americans Suffer in Silence ... From Constipation(1): ... Constipation Nation! -NEW YORK, May 28 While it ... are not comfortable talking about constipation, the results of ... discussing the topic really is: In fact, while ...
    ... Products (NYSE: APD ) announced today that ... will be presenting at the Goldman Sachs Basic Materials ... at 8:00 a.m. EDT. An audio Webcast and presentation ... web site at www.airproducts.com/Invest/PresentationSummary.htm . Air Products (NYSE: ...
    Cached Medicine News:Health News:New Book Highlights Human Cost of FDA's Failure to Investigate Medical Devices 2Health News:Cardiovascular fitness not affected by cancer treatment 2Health News:Survey Data Reveals Little Connection between Executive Compensation, Employee Bonuses and Business Ethics and Compliance 2Health News:Survey Data Reveals Little Connection between Executive Compensation, Employee Bonuses and Business Ethics and Compliance 3Health News:China Sky One Medical, Inc. Welcomes Commercial Counselor from Belgium; Looks for Business Alliance with European Companies 2Health News:China Sky One Medical, Inc. Welcomes Commercial Counselor from Belgium; Looks for Business Alliance with European Companies 3Health News:Guess What Most Americans Don't Want to Talk About (Hint: It's Not Sex!) 2Health News:Guess What Most Americans Don't Want to Talk About (Hint: It's Not Sex!) 3Health News:Guess What Most Americans Don't Want to Talk About (Hint: It's Not Sex!) 4
    Inquire...
    Inquire...
    One Pair of Knife Raising Blocks to move blade up 1 inch for adpatation of a freezing stage....
    Supercassette quick release holder for the 8000 Series sliding microtome to allow for the use of wax supercassettes, 75x52x19 mm....
    Medicine Products: